Mirae Asset Global Investments Co., Ltd. Protagonist Therapeutics, Inc Transaction History
Mirae Asset Global Investments Co., Ltd.
- $20 Billion
- Q2 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 1,751 shares of PTGX stock, worth $78,637. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,751
Previous 29,558
94.08%
Holding current value
$78,637
Previous $855,000
92.98%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding PTGX
# of Institutions
195Shares Held
58.7MCall Options Held
20.8KPut Options Held
109K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$262 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$259 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$237 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$149 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$146 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.2B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...